Oxford Immunotec Global PLC (NASDAQ:OXFD) COO Peter Edwardson sold 9,739 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $16.14, for a total transaction of $157,187.46. Following the sale, the chief operating officer now owns 92,905 shares of the company’s stock, valued at approximately $1,499,486.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Peter Edwardson also recently made the following trade(s):

  • On Monday, August 7th, Peter Edwardson sold 22,371 shares of Oxford Immunotec Global PLC stock. The shares were sold at an average price of $17.70, for a total transaction of $395,966.70.

Oxford Immunotec Global PLC (OXFD) traded up 0.69% during mid-day trading on Wednesday, hitting $16.13. 125,073 shares of the company were exchanged. Oxford Immunotec Global PLC has a 12-month low of $9.38 and a 12-month high of $19.51. The company’s 50-day moving average is $16.85 and its 200 day moving average is $15.21. The company’s market capitalization is $372.22 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting analysts’ consensus estimates of ($0.32). The company had revenue of $26.10 million for the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. Oxford Immunotec Global PLC’s revenue was up 35.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.29) earnings per share. Analysts expect that Oxford Immunotec Global PLC will post ($1.65) EPS for the current year.

WARNING: “Oxford Immunotec Global PLC (OXFD) COO Peter Edwardson Sells 9,739 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/16/oxford-immunotec-global-plc-oxfd-coo-peter-edwardson-sells-9739-shares.html.

A number of institutional investors have recently made changes to their positions in OXFD. Endurant Capital Management LP increased its position in shares of Oxford Immunotec Global PLC by 3,456.1% in the first quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock worth $8,844,000 after buying an additional 554,915 shares in the last quarter. AXA increased its position in shares of Oxford Immunotec Global PLC by 52.5% in the first quarter. AXA now owns 917,468 shares of the company’s stock worth $14,212,000 after buying an additional 315,718 shares in the last quarter. Redmile Group LLC increased its position in shares of Oxford Immunotec Global PLC by 17.9% in the first quarter. Redmile Group LLC now owns 2,004,849 shares of the company’s stock worth $31,055,000 after buying an additional 303,800 shares in the last quarter. Granahan Investment Management Inc. MA purchased a new position in shares of Oxford Immunotec Global PLC during the first quarter worth $4,577,000. Finally, Renaissance Technologies LLC increased its position in shares of Oxford Immunotec Global PLC by 97.8% in the first quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock worth $5,628,000 after buying an additional 179,600 shares in the last quarter. 84.96% of the stock is owned by institutional investors and hedge funds.

Several analysts have commented on the stock. Piper Jaffray Companies reiterated a “buy” rating and set a $26.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BTIG Research reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th. Finally, Cowen and Company reiterated a “buy” rating and set a $22.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Oxford Immunotec Global PLC has an average rating of “Hold” and an average price target of $21.00.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.